IGF2 and colorectal carcinoma: These results contribute to explaining the increased aggressiveness and resistance to specific EGFR targeting of CRC overexpressing the IGF2/miRNA‐483 locus and provide a rationale for therapeutic strategies aimed at extensive EGFR family inhibition.